Incretin-Based Therapy in Patients with Renal Disease
Click here to view our current activities in Diabetes.
Renal dysfunction is a common problem in diabetic patients, with approximately 40% of patients developing diabetic kidney disease. Since even mild renal impairment is associated with a markedly increased risk of cardiovascular disease and death, identifying patients with impaired renal function is critical for effective patient management. In addition, many antidiabetic medications have adverse effects on renal function and/or increase the risk of other treatment-related side effects in patients with impaired renal function. Join Jaime A. Davidson, MD as he discusses the issues involved in assessing and monitoring renal function in all diabetic patients, choosing optimal antidiabetic treatment in patients with renal dysfunction, and the role of the new incretin-based agents in this patient population.
Jaime A. Davidson, MD
- Clinical Professor of Medicine
- Department of Endocrinology, Diabetes, and Metabolism
- Touchstone Diabetes Research Center
- University of Texas
- Southwestern Medical Center
- Dallas, Texas
Jaime A. Davidson, MD, is a consultant for, on the advisory board of, and/or on the speakers bureau of Abbott Laboratories, Animas Corporation, AstraZeneca, Bristol-Myers Squibb, Cure-DM, Inc, Eli Lilly and Company, Generex Biotechnology Corporation, GlaxoSmithKline, Johnson & Johnson (LifeScan), Merck Serono, Merck Sharp & Dohme Corporation, Novo Nordisk Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Pfizer, Inc, Roche Pharmaceuticals, sanofi-aventis, and Takeda Pharmaceutical Company, Ltd.
Mark E. Molitch, MD, has received consulting fees from Abbott Laboratories, Corcept Therapeutics, and Novartis Pharmaceuticals Corporation; and has performed contracted research for Corcept Therapeutics and Novartis Pharmaceuticals Corporation.
Charles Reasner, MD, has received salary/honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Novo Nordisk Pharmaceuticals, Inc, and Takeda Pharmaceutical Company Limited.
Available for CME/CE:
Physicians
Publish Date: May 18, 2012 Termination Date: May 17, 2013Nurses
Publish Date: May 18, 2012 Termination Date: May 17, 2013Pharmacists
Publish Date: May 18, 2012 Termination Date: May 17, 2013Estimated time for completion of this activity:
CNE: 30.00 minutes
CPE: 30.00 minutes
Target Audience
This activity is designed for diabetologists, endocrinologists, internists, primary care physicians, nurse practitioners, nurses, and pharmacists who participate in the care of patients with type 2 diabetes.
Activity Goal
The goal of this CME/CPE/CE activity is to provide up-to-date information and multiple perspectives on the evolving pathogenesis and complications of T2DM as well as current and emerging treatments and best practices in the management of patients with T2DM.
Learning Objective (s)
- Evaluate the benefits and risks and the need for dosage reduction associated with anti-diabetic therapies in choosing the most appropriate therapy for individual diabetic patients with renal insufficiency.
- Assess renal function in all diabetic patients prior to initiating anti-diabetic therapy and on a regular basis.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 0.50 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This podcast series is worth up to 0.5 contact hour (0.05 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-12-1156-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Jaime A. Davidson, MD is a consultant for, on the advisory board of, and/or on the speakers bureau of Abbott Laboratories, Animas Corporation, AstraZeneca, Bristol-Myers Squibb, Cure-DM, Inc, Eli Lilly and Company, Generex Biotechnology Corporation, GlaxoSmithKline, Johnson & Johnson (LifeScan), Merck Serono, Merck Sharp & Dohme Corporation, Novo Nordisk Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Pfizer, Inc, Roche Pharmaceuticals, sanofi-aventis, and Takeda Pharmaceutical Company, Ltd.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Karen Gravelle, PhD - medical writer, has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Zachary Bloomgarden, MD has received salary/honoraria from Amylin Pharmaceuticals, Inc, Daiichi Sankyo Company, Limited, Eli Lilly and Company, GlaxoSmithKline, Inc, Merck & Co, Inc, and Novo Nordisk, Inc; has received consulting fees from AstraZeneca, AtheroGenics, Inc, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo Company, Limited, Dainippon Sumitomo Pharma America, Inc, Forest Laboratories, Inc, Medtronic, Inc, Merck & Co, Inc., Nastech Pharmaceutical Company, Novartis Pharmaceuticals Corporation, and Takeda Pharmaceutical Company Limited; and has ownership interest in Abbott Laboratories, Bard, Inc, Hoffmann-La Roche Inc, Medtronic, Inc, Merck & Co, Inc, Millipore, and Novartis Pharmaceuticals Corporation.
Jaime A. Davidson, MD is a consultant for, on the advisory board of, and/or on the speakers bureau of Abbott Laboratories, Animas Corporation, AstraZeneca, Bristol-Myers Squibb, Cure-DM, Inc, Eli Lilly and Company, Generex Biotechnology Corporation, GlaxoSmithKline, Johnson & Johnson (LifeScan), Merck Serono, Merck Sharp & Dohme Corporation, Novo Nordisk Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Pfizer, Inc, Roche Pharmaceuticals, sanofi-aventis, and Takeda Pharmaceutical Company, Ltd.
Mark E. Molitch, MD has received consulting fees from Abbott Laboratories, Corcept Therapeutics, and Novartis Pharmaceuticals Corporation; and has performed contracted research for Corcept Therapeutics and Novartis Pharmaceuticals Corporation.
Charles Reasner, MD has received salary/honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Novo Nordisk Pharmaceuticals, Inc, and Takeda Pharmaceutical Company Limited.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: May 18, 2012 Termination Date: May 17, 2013Nurses
Publish Date: May 18, 2012 Termination Date: May 17, 2013Pharmacists
Publish Date: May 18, 2012 Termination Date: May 17, 2013Estimated time for completion of this activity:
CNE: 30.00 minutes
CPE: 30.00 minutes
Target Audience
This activity is designed for diabetologists, endocrinologists, internists, primary care physicians, nurse practitioners, nurses, and pharmacists who participate in the care of patients with type 2 diabetes.
Activity Goal
The goal of this CME/CPE/CE activity is to provide up-to-date information and multiple perspectives on the evolving pathogenesis and complications of T2DM as well as current and emerging treatments and best practices in the management of patients with T2DM.
Learning Objective (s)
- Evaluate the benefits and risks and the need for dosage reduction associated with anti-diabetic therapies in choosing the most appropriate therapy for individual diabetic patients with renal insufficiency.
- Assess renal function in all diabetic patients prior to initiating anti-diabetic therapy and on a regular basis.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 0.50 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This podcast series is worth up to 0.5 contact hour (0.05 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-12-1156-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Jaime A. Davidson, MD is a consultant for, on the advisory board of, and/or on the speakers bureau of Abbott Laboratories, Animas Corporation, AstraZeneca, Bristol-Myers Squibb, Cure-DM, Inc, Eli Lilly and Company, Generex Biotechnology Corporation, GlaxoSmithKline, Johnson & Johnson (LifeScan), Merck Serono, Merck Sharp & Dohme Corporation, Novo Nordisk Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Pfizer, Inc, Roche Pharmaceuticals, sanofi-aventis, and Takeda Pharmaceutical Company, Ltd.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Karen Gravelle, PhD - medical writer, has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Zachary Bloomgarden, MD has received salary/honoraria from Amylin Pharmaceuticals, Inc, Daiichi Sankyo Company, Limited, Eli Lilly and Company, GlaxoSmithKline, Inc, Merck & Co, Inc, and Novo Nordisk, Inc; has received consulting fees from AstraZeneca, AtheroGenics, Inc, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo Company, Limited, Dainippon Sumitomo Pharma America, Inc, Forest Laboratories, Inc, Medtronic, Inc, Merck & Co, Inc., Nastech Pharmaceutical Company, Novartis Pharmaceuticals Corporation, and Takeda Pharmaceutical Company Limited; and has ownership interest in Abbott Laboratories, Bard, Inc, Hoffmann-La Roche Inc, Medtronic, Inc, Merck & Co, Inc, Millipore, and Novartis Pharmaceuticals Corporation.
Jaime A. Davidson, MD is a consultant for, on the advisory board of, and/or on the speakers bureau of Abbott Laboratories, Animas Corporation, AstraZeneca, Bristol-Myers Squibb, Cure-DM, Inc, Eli Lilly and Company, Generex Biotechnology Corporation, GlaxoSmithKline, Johnson & Johnson (LifeScan), Merck Serono, Merck Sharp & Dohme Corporation, Novo Nordisk Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Pfizer, Inc, Roche Pharmaceuticals, sanofi-aventis, and Takeda Pharmaceutical Company, Ltd.
Mark E. Molitch, MD has received consulting fees from Abbott Laboratories, Corcept Therapeutics, and Novartis Pharmaceuticals Corporation; and has performed contracted research for Corcept Therapeutics and Novartis Pharmaceuticals Corporation.
Charles Reasner, MD has received salary/honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Novo Nordisk Pharmaceuticals, Inc, and Takeda Pharmaceutical Company Limited.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
||||||||||||||||||
|
Renal dysfunction is a common problem in diabetic patients, with approximately 40% of patients developing diabetic kidney disease. Since even mild renal impairment is associated with a markedly increased risk of cardiovascular disease and death, identifying patients with impaired renal function is critical for effective patient management. In addition, many antidiabetic medications have adverse effects on renal function and/or increase the risk of other treatment-related side effects in patients with impaired renal function. Join Jaime A. Davidson, MD as he discusses the issues involved in assessing and monitoring renal function in all diabetic patients, choosing optimal antidiabetic treatment in patients with renal dysfunction, and the role of the new incretin-based agents in this patient population.
|
||||||||||||||||||



